Sinclair Research, providers of preclinical services, announced new executive leadership with the arrival of G. Alex Wakefield, DVM, as VP of Research and Operations.
In this newly created role, Wakefield will have overall responsibility for the company’s research services and its operational processes. He will be responsible for driving the growth of Sinclair’s business model and fostering positive relationships with new and current customers.
Wakefield joins Sinclair Research from Covance in Greenfield, here he served in multiple areas including discovery science, toxicology, veterinary services, business development and management.
He has held similar positions at Eli Lilly and company. With more than 25 years of industry experience, Wakefield is an accomplished pharmaceutical development professional with extensive expertise in the science and management of drug development.
His preclinical market knowledge and experience from the pharmaceutical and contract research organisation industries will be of significant value to Sinclair and all its customers.
“Alex’s combination of experience across pharma and CRO services coupled with his scientific knowledge of both efficacy and safety animal modelling will enable Sinclair to move to the next level in size, scope and market leadership” said Guy Bouchard, President of Sinclair Research.
“2017 was an outstanding year for Sinclair Research, particularly related to GLP services and regulatory compliance. As a seasoned industry executive, Alex’s proven leadership skills will be invaluable as we continue to grow our business.”
